-+ 0.00%
-+ 0.00%
-+ 0.00%

On October 30, Huaxi Biotech announced that the company's strategic investment in Korea's botulinum toxin INIBO has been approved by the State Drug Administration, and the company is its sole partner in the mainland China market.

Zhitongcaijing·10/30/2026 07:49:08
Listen to the news
On October 30, Huaxi Biotech announced that the company's strategic investment in Korea's botulinum toxin INIBO has been approved by the State Drug Administration, and the company is its sole partner in the mainland China market.